What Coffeinum N Treats: Main Uses and Benefits

Coffeinum N, which contains the active substance Caffeine, is generally used to provide supportive therapeutic benefits across domains where additional symptomatic support is needed, primarily focused on restoring alertness and providing targeted symptom relief. This substance may be used for the short-term relief of fatigue or drowsiness.

This preparation is commonly used across conditions presenting with acute episodes related to three primary symptom domains:

• Temporary neurological fatigue (relevant for managing drowsiness, mental exhaustion, and impaired concentration).
• Vascular headaches (applied for relief of severe, postural pain, such as post-dural puncture headache).
• Specialized neonatal respiratory needs (used for addressing clinically significant breathing pauses in premature infants).

In these scenarios, Coffeinum N assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

---

Quick Facts: Therapeutic Domains

Domain	Symptom/Condition Category	Patient Benefit
CNS Activation	Acute fatigue, drowsiness, impaired focus	Contributes to improved day-to-day comfort by promoting wakefulness.
Vascular Support	Post-dural puncture headache (PDPH), severe pain	Assists with maintaining functional stability during symptomatic episodes.
Respiratory Support	Apnea of prematurity (AOP)	Supports the patient during difficult episodes by assisting with stabilizing respiratory rhythm.

Regulatory References

1. NIH MedlinePlus overview of Caffeine

Who Can and Cannot Use Coffeinum N?

The eligibility for Coffeinum N is strictly defined by regulatory documents, focusing on age and specific pre-existing conditions.

Official Eligibility Status

Classification	Population/Condition
Contraindicated	Patients with known hypersensitivity to caffeine or any component of the formulation.
Eligible	Adults and adolescents ge 12 years for alertness; Preterm neonates (28 to <33 weeks gestational age) for apnea of prematurity.
Not Recommended	Children under 12 years of age for alertness preparations.

---

Eligibility-Related Restrictions

Regulatory caution is required for individuals with impaired renal or hepatic function, as the body's slower clearance can increase the drug's effects. Use is also restricted, requiring careful monitoring, in infants with a history of seizure disorders or cardiovascular disease. Before treating a neonate, other underlying causes for the condition, such as sepsis, must be ruled out or properly addressed. Use in pregnant individuals requires caution, although use while breastfeeding is generally considered low-risk to the infant.

Caffeine, the active substance in Coffeinum N, can interact with numerous medicines, altering their effects or increasing the risk of side effects. It is essential to inform your doctor or pharmacist about all medications and supplements you are taking.

Potential Drug Interactions

Category	Examples of Medicines	Potential Effect of Interaction
Central Nervous System Stimulants	Ephedrine, Pseudoephedrine, Amphetamines	Increased risk of serious side effects, including increased heart rate and high blood pressure.
Enzyme Inhibitors	Cimetidine, Fluoroquinolone antibiotics (e.g., Ciprofloxacin), Oral Contraceptives	These medicines can inhibit the breakdown of caffeine, leading to a build-up of caffeine in the body. This may increase caffeine's stimulating effects and adverse reactions like insomnia and jitteriness.
Methylxanthines	Theophylline	Concurrent use may enhance the side effects of Theophylline, such as nausea, insomnia, and rapid heartbeat, due to both being in the same drug class.
Antiarrhythmics / Antiplatelet Drugs	Adenosine, Dipyridamole, Warfarin, Aspirin	Caffeine can reduce the effectiveness of Adenosine and Dipyridamole, particularly in cardiac stress tests. With blood thinners like Warfarin and Aspirin, caffeine might slow blood clotting, increasing the risk of bleeding.
Antiseizure Medications	Phenobarbital, Phenytoin	Caffeine can potentially reduce the effectiveness of these medications, which could increase the risk of seizures.

Additionally, alcohol may increase the risk of adverse cardiovascular effects when consumed with Coffeinum N. Patients taking Lithium should know that caffeine can increase how quickly the body removes Lithium, potentially reducing its therapeutic effect. Always follow the advice of a healthcare professional regarding caffeine consumption while on medication.

The mechanism of action for Coffeinum N (Caffeine) is centered on its function as a competitive antagonist of adenosine receptors, initiating a central cascade that results in psychomotor stimulation.

Primary Mechanism: Antagonism of Inhibitory Adenosine Signals

This domain covers the drug's core action as a non-selective antagonist of adenosine receptors (A1 and A2A) within the central nervous system. By blocking these receptors, Caffeine prevents the binding of the inhibitory neuromodulator, Adenosine, thereby disinhibiting nerve cell activity. This initial molecular step results in increased neuronal firing and psychomotor activity.

Systemic Consequence: Indirect Modulation of Excitatory Pathways

The subsequent cascade involves the indirect enhancement of several excitatory neurotransmitter systems, including those involving dopamine and norepinephrine. By removing the adenosine-mediated inhibition, the drug permits an increased release of these transmitters, leading to changes in the signaling balance that result in an increased state of central nervous system arousal. This mechanism also causes cerebral vasoconstriction by antagonizing A2 receptors in the cerebral vasculature.

Concentration-Dependent Secondary Mechanisms (Smooth Muscle and Cardiac Effects)

At higher concentrations, the drug engages a separate mechanistic domain: the non-selective inhibition of Phosphodiesterase (PDE) enzymes. This enzyme inhibition raises intracellular cAMP levels, which modulates the contractility of smooth and cardiac muscle cells. This secondary mechanism results in physiological changes including bronchial smooth muscle relaxation and positive cardiostimulation.

Official Administration Guidelines for Coffeinum N

The usage of Coffeinum N (Caffeine/Caffeine Citrate) is structured into two distinct, established patterns: intermittent oral use for adult alertness and a highly specialized, supervised regimen for neonates. The official instructions define the precise routes, dosing schedules, and administration constraints for each context.

---

Administration Scope and Dosing

Category	Adult Alertness Use (Oral Tablets)	Neonatal Apnea of Prematurity Use (Solution)
Route of Administration	Oral (PO)	Intravenous (IV), or Oral (PO) for maintenance
Dosing Schedule	100 mg to 200 mg (Caffeine base) per dose	Loading Dose: 20 mg/kg Caffeine Citrate
Frequency Pattern	As-needed; not more often than every 3 to 4 hours	Loading dose is single; Maintenance dose is once every 24 hours

---

The adult oral preparation is intended for occasional use only and should be swallowed whole. The total intake is constrained by the maximum recommended frequency. Conversely, the neonatal regimen requires highly controlled administration: the intravenous loading dose must be administered by slow infusion over 30 minutes, and the maintenance dose requires either a 10-minute IV infusion or accurate oral administration. Treatment in this specialized population is confined to infants with specific gestational age criteria and must occur under the supervision of a physician experienced in neonatal intensive care.

Research Evidence / Overview of Studies for Coffeinum N

This overview provides a non-technical summary of the formal research that has been studied for the medicinal uses of Coffeinum N (Caffeine), describing the types of trials conducted, the outcomes measured, and the areas where certainty remains low or research is ongoing.

---

Evidence for Use in Specialized Neonatal Respiratory Needs (Apnea of Prematurity)

This area has been studied for use in preterm infants, primarily involving large-scale Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. Researchers examined short-term outcomes such as the frequency of apnea episodes, duration of mechanical ventilation, and complications like Bronchopulmonary Dysplasia (BPD). Findings describe patterns observed in the studies regarding extubation success rates. Long-term follow-up studies extending up to 11 years monitored neurodevelopmental outcomes and survival. Investigation is still needed to characterize the optimal dosing regimen and the most effective timing for initiation of administration.

Evidence for Use in Managing Vascular Headaches

The compound was studied for Post-Dural Puncture Headache (PDPH). The evidence base includes smaller RCTs and Systematic Reviews that examined pain severity and the time to reported relief. Findings were mixed across studies, and the compound was evaluated in combination regimens. Assessing the compound's isolated contribution is challenging. Sample sizes were modest in some trials, and limited information for long-term outcomes exists regarding sustained relief.

Evidence for Use in Temporary Neurological Fatigue and Alertness

The compound was observed in numerous Behavioral and Cognitive Trials focusing on healthy adults and those with sleep deprivation. Researchers examined outcomes reflecting daily functioning, such as vigilance scales and reaction time. The majority of this evidence focuses on acute or single-session administration, meaning follow-up durations were limited to the immediate effect. Data for certain groups, such as older adults, remain insufficient.

What Is Still Uncertain About Coffeinum N Research

Across all indications, long-term effects are not fully established, and follow-up durations were limited in many studies. For headaches, the compound's influence as part of combination regimens is an area of ongoing research. For neonatal use, research is still needed to establish the optimal dosing regimen and the best timing for administration.

Key Studies & References

1. Caffeine for Headaches: Helpful or Harmful? A Brief Review of the Literature
2. Label: ALERT- caffeine tablet (DailyMed / FDA)

Common questions about Coffeinum N (FAQ)

Q: How quickly does Coffeinum N start working after you take it?

According to official product information, Coffeinum N typically reaches its highest level in the blood (maximum concentration) between 30 minutes and 2 hours after being taken. This timeframe gives an indication of when the medication's effects might begin to be noticeable for most people.

---

Q: What should I do if I miss a scheduled dose of Coffeinum N?

Regulatory documents state that if a dose is forgotten, you should not take a double dose to make up for the missed one. The recommended action is to continue with the next dose at the regularly scheduled time. Following the prescribed schedule is generally important for medication use.

---

Q: Can I stop taking Coffeinum N suddenly, or do I need to decrease the amount first?

Official information indicates that if Coffeinum N use is stopped suddenly, side effects may occur as a result of withdrawal. These effects can include headaches, tiredness, and flu-like symptoms. A healthcare provider should be consulted for guidance on gradually reducing the dose.

---

Q: Is Coffeinum N known to cause any long-term health issues or dependence?

Studies and official information indicate that long-term, high-dose use of products containing the active ingredient in Coffeinum N may lead to dependence. When dependence occurs, abruptly stopping the medicine can lead to withdrawal symptoms. Regulatory information does not currently identify long-term health issues specifically linked to use of the drug as prescribed.

---

Q: Does Coffeinum N affect my ability to drive or operate machinery safely?

Official product information states that the medicine may affect ability to drive or use machinery safely, particularly due to the potential for side effects like dizziness or fatigue. If these effects occur, it is generally recommended to avoid driving or operating complex machinery until the individual is certain these tasks can be performed safely.

---

Q: Can I drink alcohol while taking Coffeinum N?

Regulatory documents state that consuming alcohol while taking Coffeinum N is generally not recommended. Combining the two may increase the risk of certain side effects, such as nervousness and difficulty sleeping. Patients are generally advised to avoid alcohol to prevent any potential negative interactions.

---

Q: Is Coffeinum N safe to use during pregnancy or while breastfeeding?

According to official regulatory sources, the medicine should not be used during pregnancy. The active ingredient is known to pass into breast milk. Therefore, official product information advises against using Coffeinum N while breastfeeding.

Storage Conditions and Container Rules

Coffeinum N tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with some labels allowing up to 30 C. Storage requires avoiding excessive heat and humidity and keeping the tablet container tightly closed. The individual vials of Caffeine Citrate Oral Solution must always be stored in the child-resistant outer container.

Handling and Disposal

All forms must be stored out of the sight and reach of children. The liquid solution is for single use only, and any unused portion must be discarded immediately after opening because the vial is preservative-free. For disposal, the drug should not be flushed down the toilet. If a drug take-back program is unavailable, unused medicine must be mixed with an unappealing substance (such as coffee grounds) and placed in a sealed container before being thrown into the household trash.